That’s ridiculous because they have plenty of shares to issue if they need to. There is absolutely NOTHING that suggests “dire straights”. If this were dire straights they’d not be getting a loan that doesn’t have to be paid for a while. Plus they are licensed to sell now, prior to marketing license, how many companies have that in the history of biotech. I don’t know any. And they are about to be licensed to manufacture commercially.
These false light narratives are ridiculous and completely bogus.
This is not a company highly in debt. The fact that they can borrow these modest amounts to get licensed and MHRA, EMA and probably FDA licensed and get production ready is impressive.
News 
Market Data 
Discover 
